These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 33322239)

  • 1. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
    McAnulty J; DiFeo A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
    [No Abstract]   [Full Text] [Related]  

  • 2. MYC on the path to cancer.
    Dang CV
    Cell; 2012 Mar; 149(1):22-35. PubMed ID: 22464321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule modulators of c-Myc/Max and Max/Max interactions.
    Berg T
    Curr Top Microbiol Immunol; 2011; 348():139-49. PubMed ID: 20680803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
    Struntz NB; Chen A; Deutzmann A; Wilson RM; Stefan E; Evans HL; Ramirez MA; Liang T; Caballero F; Wildschut MHE; Neel DV; Freeman DB; Pop MS; McConkey M; Muller S; Curtin BH; Tseng H; Frombach KR; Butty VL; Levine SS; Feau C; Elmiligy S; Hong JA; Lewis TA; Vetere A; Clemons PA; Malstrom SE; Ebert BL; Lin CY; Felsher DW; Koehler AN
    Cell Chem Biol; 2019 May; 26(5):711-723.e14. PubMed ID: 30880155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
    D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
    J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MYC-WDR5 Nexus and Cancer.
    Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
    Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
    Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
    Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.
    Maltais L; Montagne M; Bédard M; Tremblay C; Soucek L; Lavigne P
    PLoS One; 2017; 12(3):e0174413. PubMed ID: 28350847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
    Allen-Petersen BL; Sears RC
    BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
    Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
    J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
    [No Abstract]   [Full Text] [Related]  

  • 11. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
    Pelengaris S; Khan M
    Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC, Metabolic Synthetic Lethality, and Cancer.
    Hsieh AL; Dang CV
    Recent Results Cancer Res; 2016; 207():73-91. PubMed ID: 27557535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A big step for MYC-targeted therapies.
    Atibalentja DF; Deutzmann A; Felsher DW
    Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC as a target for cancer treatment.
    Duffy MJ; O'Grady S; Tang M; Crown J
    Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.
    Jiang H; Bower KE; Beuscher AE; Zhou B; Bobkov AA; Olson AJ; Vogt PK
    Mol Pharmacol; 2009 Sep; 76(3):491-502. PubMed ID: 19498040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.
    Chen BJ; Wu YL; Tanaka Y; Zhang W
    Int J Biol Sci; 2014; 10(10):1084-96. PubMed ID: 25332683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells.
    Shah M; Rennoll SA; Raup-Konsavage WM; Yochum GS
    Cell Cycle; 2015; 14(3):323-32. PubMed ID: 25659031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
    Link JM; Hurlin PJ
    Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.